Ocugen, Inc. (OCGN) Stock

Ocugen, Inc. (OCGN) is a Healthcare stock trading at $1.27 (as of 2026-06-18), with a market capitalization of $467.16M and a trailing P/E of -23.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ocugen, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for blindness-related conditions. Its pipeline includes gene therapy candidates OCU400 and OCU410 and a preclinical fusion protein, OCU200, aimed at inherited retinal diseases and retinal disorders such as dry age-related macular degeneration.

Valuation — source: SEC EDGAR (first-party)
Price	$1.27
Market Cap	$467.16M
P/E Ratio	-23.0
EV / EBITDA	-7.3
Price / Book	80.48
Price / Sales	104.63
DCF Value (model)	$-3.00
DCF Upside vs Price	-336.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.41M
Net Margin	-1537.4%
Return on Equity	-1234.7%
Debt / Equity	5.03
Current Ratio	1.86
Revenue Growth (YoY)	8.8%
FCF Growth (YoY)	25.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-13.28 (distress)

Valuation vs Sector & Industry
Stock P/E	-23.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-210.1%
vs Industry	-235.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD CAPITAL MANAGEMENT LLC ($24.99M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Shankar Musunuri
Employees	95
Country	US
IPO Date	2014-12-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.